Nanostics is a privately held company focused on the development and commercialization of novel, non-invasive diagnostic tests for cancer and other diseases. The technology at the core of Nanostics is an advanced liquid biopsy platform and state of the art machine learning algorithm for accurate diagnoses from a variety of bodily fluids. The technology is applicable to a wide range of diseases including prostate, bladder, and pancreatic cancers, as well as neurodegenerative diseases. Nanostics’ lead product, ClarityDX Prostate, is the most accurate diagnostic test to diagnose clinically significant prostate cancer, and is positioned to emerge as the world’s leading diagnostic tool for prostate cancer.
Privately Funded Company
Company HQ State:
Company HQ Country:
Main Therapeutic Focus:
Lead Product in Development:
Development Phase of Primary Product:
Number Of Unlicensed Products (For Which You Are Seeking Partners):